Gemcitabine (DBL)™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

Listen to the audio transcription of the CMI leaflet.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

DBL Gemcitabine Injection is indicated: 1. For treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). 2. For treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. 3. For treatment of patients with FU refractory pancreatic cancer. 4. Alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. 5. In combination with paclitaxel, for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. 6. In combination with carboplatin, for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.

Source: ARTG

• Shelf lifetime is 24 Months
• Store at 2 to 8 degrees Celsius
• Do not Freeze; Refrigerate

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, solution
• Intravenous
• A clear, colourless or light straw-coloured solution in a clear glass vial

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• Single

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 October 2026, under PBS item codes 7246J (Opens in new tab) and 4439P (Opens in new tab). Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: Gemcitabine

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).